Predicting individual GLP-1 response, before the first prescription.
9 in 10 GLP-1 patients never complete their first year. First Dose predicts who will respond, who will struggle, and why, so your patients stay on therapy.
The problem
The drug works. The matching doesn't.
GLP-1 patients never complete their first year of therapy.
Most don't fail the drug. The drug fails them.
Spent on GLP-1s in the US annually. Much of it prescribed to patients who will discontinue within months.
The waste isn't a billing problem. It's a precision problem.
Of discontinuations have side effects as a documented reason. Many of them predictable before the first dose.
We already know who will struggle. We just haven't been using that knowledge.
These aren't failures of medicine. They're failures of matching.
How it works
How First Dose works
One pipeline, three stages: from raw patient signals to a prescription a clinician can act on.
Starting with GLP-1s. Built for every drug class.
Medicine has treated populations for 200 years. We're building the infrastructure to treat individuals. If that matters to you, let's talk.
For clinics
Reduce side effects. Improve retention. Prescribe with precision. Join the growing number of telehealth providers using First Dose to match patients to the right medication before they take it.
Partner with First Dose →For investors & partners
The precision layer for medicine doesn't exist yet. We're building it, starting with the drug decision, expanding to the full picture of individual health. If you want to be part of that, we want to hear from you.
Get in touch →